Contract Development and Manufacturing Organization (CDMO) Market to Hit USD 465.14 Billion by 2032; Charles River Laboratories Released Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing

The global Contract Development and Manufacturing Organization (CDMO) market size was valued at USD 224.86 billion in 2023. The market is projected to grow from USD 242.62 billion in 2024 to USD 465.14 billion by 2032, exhibiting a CAGR of 8.5% during the forecast period. Fortune Business Insights™ presents this information in its report titled Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Industry Analysis, By Service (CMO [API Manufacturing, Finished Product Manufacturing {Solid Dosage Forms, Injectables, and Others}, and Packaging] and CRO [Early Phase Development Services {Chemistry, Manufacturing and Controls (CMC), Preclinical Service, and Discovery}, Clinical {Phase 1, Phase 2, Phase 3, and Phase 4}, Laboratory Service, and Others]), and Regional Forecast, 2024-2032

Contract Development and Manufacturing Organizations (CDMOs) entail the complete process from drug discovery to commercialization. The shortage of in-house manufacturing processes and capabilities in small pharmaceutical firms and growing complexities in therapies are stimulating market growth.

The Contract Development and Manufacturing Organization (CDMO) market observed a slight moderate positive growth in 2020 than the previous year. Despite this, the research and production efforts of several pharmaceutical and biopharmaceutical industry players were boosted in the latter phase of 2020 to develop and distribute vaccines, medications, and testing kits for the SARS-CoV-2 virus. In the post-COVID-19 scenario, there was a significant expansion in the market due to growth in awareness of outsourcing of clinical trials and manufacturing, specifically biologics, and the resumption of postponed clinical trials and early phase development services.

Worldwide Clinical Trials Expands Global Reach with Strategic Collaboration in Spain

Worldwide Clinical Trials announced its collaboration with NEXT Oncology in Spain and Pratia Research through its Site Alliance Collaboration in May 2023. This partnership marks a significant step in expanding the company's presence beyond the U.S. market, reinforcing its commitment to delivering exceptional clinical research services worldwide.

Surging Demand for Pharmaceutical and Biopharmaceutical Products to Support Market Growth

The world is witnessing a rise in the number of chronic disorders owing to the uptake of Western lifestyle, development in the economy, and increase in population. Effective medical products are being created by pharmaceutical firms to boost treatment owing to a surge in the aging population and chronic disorders.

However, the strict regulatory scenarios, along with restricted funds for R&D may hinder Contract Development and Manufacturing Organization (CDMO) market growth.

Top Players Deploy Product Innovations to Gain a Competitive Edge

Thermo Fisher Scientific Inc., Parexel International Corporation, Vetter, and Unither are some of the leading companies in the market. They are focusing on different strategic developments, including collaborations, partnerships, and service expansion. Many players are also emphasizing releasing innovative Contract Development and Manufacturing Organization (CDMO) services to achieve a competitive advantage.

Key Industry Development

• March 2023 - Charles River Laboratories unveiled an off-the-shelf pHelper offering, which is developed to streamline and secure Adeno-Associated Virus (AAV)-based gene therapy programs. These products are instantly available in good manufacturing practice, high quality, and research-grade.

List of Key Players Mentioned in the Report:

• IQVIA (U.S.)


• ICON plc (Ireland)


• Syneos Health (U.S.)


• Vetter (Germany)


• Parexel International (MA) Corporation (U.S.)


• Recipharm AB (Sweden)


• Curia Global, Inc. (U.S.)


• Thermo Fisher Scientific Inc. (U.S.)


• Unither (France)


• DPT Laboratories, LTD. (U.S.)


• NextPharma Technologies (U.S.)


• Lonza (Switzerland)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502

Further Report Findings:

• North America market is anticipated to occupy the largest share during the assessment period on account of the presence of well-developed CDMOs. The increasing number of registered clinical trials, specifically in the U.S., is also expediting regional expansion. The data obtained from clinicaltrials.gov reported 477,346 clinical trials across the globe, with U.S. accounting for 30% (145,575) of these trials.


• Europe captured a moderate Contract Development and Manufacturing Organization (CDMO) market share in 2023, which can be credited to growing investments by pharmaceutical companies in R&D activities. This, along with a rising demand for effective treatments for chronic ailments, is stimulating regional growth.


• In 2023, the Contract Manufacturing Organization (CMO) segment led the global Contract Development and Manufacturing Organization (CDMO) market share. This growth is primarily attributed to the rising number of contract manufacturing organizations offering advanced manufacturing solutions.

Table of Segmentation